Preliminary results from the TAPUR basket trial demonstrated the anti-tumor activity of palbociclib monotherapy in 29 patients with advanced STS with CDK4 amplification and no RB1 mutations (histologic subtype breakdown not reported). This evidence concerns the gene CDK4 and neoplasm.